STOCK TITAN
  1. Home
  2. News
  3. BIOL

Biolase Inc - BIOL STOCK NEWS

Welcome to our dedicated news page for Biolase (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on Biolase.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biolase's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biolase's position in the market.

News
Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024
Rhea-AI Summary
BIOLASE, Inc. reports its financial results for the fourth quarter and full year 2023, highlighting revenue growth, record consumable sales, increased adoption of laser systems, and cost savings. Despite a challenging spending environment, the company achieved modest revenue growth. The financial results show a 1% increase in net revenue, with improvements in gross margin and operating expenses. The company had cash and cash equivalents of $6.6 million as of December 31, 2023, and raised an additional $7.0 million in February 2024. Net loss and Adjusted EBITDA figures for 2023 are provided, with plans for first-quarter and full-year 2024 financial guidance, anticipating flat revenue in Q1 and a 6-8% increase in full-year revenue. BIOLASE aims to achieve positive adjusted EBITDA results for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.53%
Tags
earnings
-
News
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ:BIOL) will release its fourth quarter and full year 2023 financial and operating results on March 21, 2024. The company will host a conference call and webcast to discuss the results and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences earnings
-
News
Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ:BIOL) unveils the Waterlase iPlus Premier Edition at the Chicago Midwinter Meeting 2024, showcasing cutting-edge dental laser technology. The Premier Edition features Modular Software Design for tailored procedures, an Enhanced User Experience with a larger touchscreen display, and Comprehensive Service Support including remote diagnostics. CEO John Beaver emphasizes democratizing laser dentistry for enhanced patient care and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
News
Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'
Rhea-AI Summary
BIOLASE, Inc. (BIOL) launches 'Let's Talk Dental' webinar series to educate dental clinicians on laser technology, featuring renowned industry leaders. The series covers various dental disciplines and aims to enhance patient outcomes. The webinars will focus on topics like restorative dentistry, periodontics, pediatric dentistry, and dental hygiene, with upcoming sessions on pediatric dentistry and myofunctional therapy. The recorded webinars will be available on Education.Biolase.com, offering tailored education pathways for both all-tissue and soft-tissue lasers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ:BIOL) closes public offering of 16,000,000 units at $0.44 per unit, generating approximately $7.0 million in gross proceeds. The offering included common stock, pre-funded warrants, Class A Warrants, and Class B Warrants. Class A warrants are exercisable at $0.66 per share, while Class B warrants are exercisable at $0.748 per share upon stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ:BIOL) has been granted an extension by Nasdaq to regain compliance with Listing Rule 5550(b) by raising approximately $6.5 million through a public offering. Failure to comply by March 31, 2024, may lead to delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
News
BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
Rhea-AI Summary
BIOLASE, Inc. (BIOL) announced the pricing of a public offering of 16,000,000 units, each containing shares of common stock and warrants, at an offering price of $0.44 per unit. The gross proceeds are expected to be approximately $7.0 million. The offering is set to close on February 15, 2024, with Lake Street Capital Markets, LLC and Maxim Group LLC acting as joint placement agents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.22%
Tags
offering
-
News
BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024
Rhea-AI Summary
BIOLASE, Inc. expects continued revenue growth in 2024 and takes steps to improve operating efficiency as it pursues profitability goals. The company announced preliminary unaudited revenue results for 2023, with a projected 1% growth over 2022, generated increased adoption of its dental laser, and achieved record consumable sales. It plans to grow total full-year 2024 revenue by 6-8% and improve loss from operations by 50-60%. BIOLASE aims to achieve positive adjusted EBITDA results for 2024 and broaden participation in its dental and hygiene academies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
none
-
News
BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) experiences growing demand for its robust educational offering, resulting in an increase in the number of dental laser courses planned for the first quarter of 2024. The company offers tailored education pathways through the Waterlase Academy and Epic Diode Academy, with a wide range of classroom courses and virtual options. BIOLASE aims to expand education into facial esthetics and ensure dental clinicians are at the forefront of hygiene laser education. The company plans to continue expanding its educational offerings to enable dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
BIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARD
Rhea-AI Summary
BIOLASE, Inc. (NASDAQ: BIOL) has been awarded the Top Workplaces 2023 honor by the Inland News Group and the Orange County Register. The awards are based on employee feedback gathered through a third-party survey measuring 15 culture drivers. BIOLASE President and CEO, John Beaver, expressed gratitude for the dedication and passion of their employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
Stock BIOL logo
Biolase Inc

Nasdaq:BIOL

BIOL Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BIOL Stock Data

4.57M
32.39M
0.34%
8.24%
7.06%
Dental Equipment and Supplies Manufacturing
Manufacturing
Link
US
Irvine

About BIOL

biolase, inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment. biolase’s products are focused on better enabling clinicians to repair and restore patient’s dental conditions while reducing the pain, fear, and anxiety generally associated with dentistry. biolase is committed to elevating the standard of care in dentistry, while enabling clinicians to achieve better business returns.